Post by
inthno on Sep 29, 2022 11:19am
AN
Time to hopefully help clear up the AN thing, Wish more people would do this rather than make suggestions or inuendos of what they think everyone else is thinking.
A direct quote from an email I sent to AN.
"Pelareorep (formally Reolysin, also known as AN1004), in-licensed from Oncolytics Biotech with exclusive rights in several Asian countries, is currently still developing by us, and we expect to obtain the preliminary safety and efficacy data of the bridging trial later this year or early next year. While we have no intention to change our direction in developing anticancer drugs, our pipeline will only include the ones reflecting our focus on our global strategy"
Now we can draw our own conclusions from this. I already have my thoughts on this but each will have their own interpretation. At least AN got back to me which is better than the onc pr department of late.
Comment by
jimsenior on Oct 04, 2022 11:02am
Someone on yahoo is again questioning the interest of AN in pela. Certainly not unreasonable given the cryptic response from AN to you. I have never seen the relationship with AN as having cohesiveness. One can only hope that they (AN & ONC) have been shown a better way to advance pelareoep than spinning their wheels.